Mitochondrial myopathy patients receiving omaveloxolone, a potent NRF2 activator, for 12 weeks showed improvements in submaximal exercise tolerance and aerobic capacity, suggesting increased mitochondrial functions [141]. This evidence concerns the gene NFE2L2 and Mitochondrial myopathy.